A latest report released by Data Bridge Market Research on Global Bulbospinal Muscular Atrophy Drugs Market covering key business segments and wide scope geographies to get deep dive analysed market data. The study is a perfect balance bridging both qualitative and quantitative information of Bulbospinal Muscular Atrophy Drugs Market.
The study provides historical data (i.e. Size, Share, Volume & Value) from 2017 to 2018 and forecasted till 2026. Some are the key & emerging players that are part of coverage and have being profiled are Novartis AG, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc, Ionis Pharmaceuticals, Inc, CYTOKINETICS, INC., Others.
Global Bulbospinal Muscular Atrophy Drugs Market is growing at a steady CAGR in the forecast period of 2019-2026. The report contains data of the base year 2018 and historic year 2017. This rise in market value can be attributed to the granting of various drug designations to novel drugs by the U.S FDA, initiatives undertaken by various public, as well as nonprofit, organizations for creating awareness regarding bulbospinal muscular atrophy and increase in R&D investment by major companies.
Request For Sample Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market
Market Definition:
Bulbospinal muscular atrophy is also known as Kennedy’s disease, a rare adult-onset form of spinal muscular atrophy (SMA) is an X-linked autosomal recessive progressive neurodegenerative disorder that causes weakening and wasting of the proximal and bulbar muscles. The condition occurs due to loss of nerve cells in the brain stem and spinal cord, this result in stoppage of messages from brain to muscles for movement. Patients with bulbospinal muscular atrophy have difficulty in speaking, standing, walking and controlling their head movements. In worse condition patients can have trouble swallowing and breathing. This disorder mainly affects men and does not occur in females, who are protected by their low levels of testosterone in the body, accounting for the sex-limited inheritance pattern of this disorder.
According to National Organization for Rare Disorders, Bulbospinal muscular atrophy or Kennedy disease is a very rare type of disorder and it affects 1 in 350,000 males and rarely seen in females. The Japanese population has a very high prevalence of this disorder because of a founder effect.
Market Drivers
Growing number of incidences of spinal bulbar muscular atrophy is driving the growth of the market
Initiatives undertaken by various public, as well as nonprofit, organizations for creating awareness regarding bulbospinal muscular atrophy also acts as a market driver
Increasing healthcare expenditure can also enhance the market growth
Market Restraints
High cost of treatment for bulbospinal muscular atrophy is hindering the market growth
Lack of experienced professionals in this field can also act as a restricting factor for the growth of this market
Limited number of drugs available for bulbospinal muscular atrophy treatment also hampers the market growth
Segmentation:
By Drugs Class
5α-Reductase Inhibitors (5-ARIs)
Gonadotropin-releasing Hormone (GnRH) Agonists
Others
By Drugs
Leuprorelin
Dutasteride
Others
By Therapy
Physical Therapy
Occupational Therapy
Speech Therapy
By Treatment
Medication
Supportive Care
Surgery
By Route of Administration
Oral
Parenteral
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
By End-Users
Hospitals
Homecare
Specialty Clinics
By Geography
North America
Europe
Asia-Pacific
South America
Middle East & Africa
For More Details In-Depth Inquiry @ https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market
Key Developments in the Market
In April 2019, Novartis AG is developing BVS857, a novel drug for the treatment of bulbospinal muscular atrophy, currently ongoing in phase ll clinical trial. If approved this novel drug will provide a potential treatment for patients with bulbospinal muscular atrophy and help in improving their life
In August 2018, Takeda Pharmaceutical Company Limited is developing Leuprorelin, a gonadotropin-releasing hormone (GnRH) agonist for the treatment of bulbospinal muscular atrophy. If approved this drug will provide a potential treatment for patients with bulbospinal muscular atrophy
Competitive Analysis:
Global bulbospinal muscular atrophy drugs market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of bulbospinal muscular atrophy drugs market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.
The key market players in the global bulbospinal muscular atrophy drugs market are Novartis AG, F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Pfizer Inc, Ionis Pharmaceuticals, Inc, CYTOKINETICS, INC, Regeneron Pharmaceuticals, Inc, Salarius Pharmaceuticals, Inc, Leadiant Biosciences, Inc, Abbott, Novo Nordisk A/S, Takeda Pharmaceutical Company Limited, AstraZeneca, Catalyst Pharma, PTC Therapeutics, Natera, Inc among others.
Reasons to Purchase this Report:
Current and future of global bulbospinal muscular atrophy drugs market outlook in the developed and emerging markets.
The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period.
Regions/Countries that are expected to witness the fastest growth rates during the forecast period.
The latest developments, market shares, and strategies that are employed by the major market players.
Table of Contents:
- Introduction
- Market Segmentation
- Market Overview
- Executive Summary
- Premium Insights
- Global, By Component
- Product Type
- Delivery
- Industry Type
- Geography
10.1. Overview
10.2. North America
10.3. Europe
10.4. Asia-Pacific
10.5. South America
10.6. Middle East & Africa
- Company Landscape
- Company Profiles
- Related Reports
Access Detailed TOC @ https://www.databridgemarketresearch.com/toc/?dbmr=global-bulbospinal-muscular-atrophy-drugs-market
About Data Bridge Market Research
Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Contact:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
